

Docket No. 215095US0PCT/sdc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Takashi TOJO, et al.

SERIAL NO: 09/926,385

GAU: 1614

FILED: October 24, 2001

EXAMINER:

FOR: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

1614
105/113
RECEIVED
JAN 29 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the attached International Search Report listed on the attached form PTO-1449. Copies of the reference(s) have been received by the U.S. PCT Receiving Office from the International Bureau as acknowledged in the Notification of Acceptance.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No.

24,618



22850

WILLIAM E. BEAUMONT
REGISTRATION NUMBER 30,996

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

Docket No. 215095US0PCT/sdc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Takashi TOJO, et al.
SERIAL NO: 09/926,385
FILED: October 24, 2001
FOR: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

GAU: 1614
EXAMINER:

RECEIVED
JAN 29 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.



REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the attached International Search Report listed on the attached form PTO-1449. Copies of the reference(s) have been received by the U.S. PCT Receiving Office from the International Bureau as acknowledged in the Notification of Acceptance.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

WILLIAM E. BEAUMONT
REGISTRATION NUMBER 30,996

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 215095US0PCT		SERIAL NO. 09/926,385	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Takashi TOJO, et al.			
				FILING DATE October 24, 2001		GROUP 1614	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							

FOREIGN PATENT DOCUMENTS						
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO			
AO 0 644 199	03/22/95	EUROPE				
AP 0 535 959	04/07/93	EUROPE				
AQ WO 96/11210	04/18/96	WIPO				
AR						
AS						
AT						
AU						
AV						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)	
AW	R. A. ZAMBIAS, et al., Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 20, pps. 2357-2362, "ANTIFUNGAL LIPOPEPTIDES: STRUCTURE-ACTIVITY RELATIONSHIPS OF 3-HYDROXYGLUTAMINE-MODIFIED PNEUMOCANDIN BO DERIVATIVES", October 19, 1995
AX	
AY	
AZ	

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.